The Executive Team will lead the nonprofit organization on its mission of unlocking hidden cures.
NEW YORK, NEW YORK – July th, 2023 – Every Cure, a non-profit organization committed to unlocking the full potential of every drug to treat every disease it possibly can, is excited to announce it is adding leaders across healthcare to its executive team. These strategic appointments reflect Every Cure’s dedication to collaboration, innovation, and leadership in drug development and repurposing.
“I am excited to welcome our exceptional new executive team members,” said Grant Mitchell, MD, MBA, Co-founder and Chief Executive Officer of Every Cure. “Their collective expertise in data science, drug discovery, and organizational development is precisely what we need to advance our mission of delivering life-saving therapies to those who need them most.”
Introducing the New Members of the Executive Team:
- Richard Riese, MD, PhD – Dr. Riese is Chief Medical Officer at Every Cure. He is a physician scientist who brings more than 20 years of experience in the biopharmaceutical industry and academic medicine with an enduring passion for bringing medicines to patients with rare and devastating diseases. Richard has a wide breadth of clinical development experience encompassing both large and small biopharmaceuticals. He most recently served as Senior Vice President and Head of Clinical Research at Allovir, Inc, where he oversaw the clinical development of virus-specific T cells to fight latent virus infections in immunocompromised individuals. His profound expertise will be invaluable in guiding Every Cure’s efforts to identify and expedite the development of effective, repurposed therapies, ensuring that innovative treatments reach patients more swiftly and safely.
- Matej Macak, PhD – Dr. Macak is the Senior Technical Advisor to Every Cure who will be leading the AI-platform build.
- Mary Zuccato, MBA – Ms. Zuccato is the Chief Operating Officer of Every Cure. She brings a wealth of leadership experience from the finance and nonprofit sectors, having held senior management positions at both the Castleman Disease Collaborative Network (CDCN) and Vanguard. During her 13-year tenure at Vanguard, Mary served as a Senior Manager in the Corporate Strategy division, where she led diverse teams across various business lines and support functions, including Marketing, Finance, IT, and HR. Her comprehensive understanding of operational strategy and her ability to drive efficiency and innovation across organizational structures will be crucial in enhancing Every Cure’s operational capabilities. Her leadership is expected to streamline Every Cure’s internal processes and bolster the organization’s mission to develop and deliver lifesaving treatments more effectively.
- Jacqueline Grace – Ms. Grace is the Chief Development Officer at Every Cure. She brings an extensive three-decade track record of leadership in both non-profit and corporate sectors, with deep experience in international affairs and development, education and technology, and health and nutrition. Ms. Grace is profoundly committed to mission-driven work and excels in leveraging her strategic development and relationship-building skills to enhance fundraising efforts. At Every Cure, her expertise is pivotal in crafting effective fundraising strategies that attract significant support from donors, foundations, and corporate partners. Her ability to cultivate and nurture relationships with key stakeholders will be crucial in securing the necessary resources to propel Every Cure’s mission forward, enabling us to expand our drug repurposing initiatives and deliver life-saving treatments to underserved populations.
These leaders join a distinguished team, including:
- Grant Mitchell, MD, MBA – Dr. Mitchell is Co-Founder and CEO of Every Cure. He brings a rich background as an entrepreneur and investor, marked by successful launches of health technology companies and impactful CEO roles in the life science and tech sectors. Previously, Dr. Mitchell was a Principal in Analytics at McKinsey & Company’s machine learning division, QuantumBlack, where he led teams that pioneered machine learning applications in real world evidence and synthetic trials. Dr. Mitchell’s experience and leadership empowers Every Cure to harness artificial intelligence to revolutionize the drug repurposing ecosystem.
- David Fajgenbaum, MD, MBA, MSc – Dr. Fajgenbaum is Co-Founder, Chair, and Chief Scientific Officer of Every Cure and a physician-scientist at the University of Pennsylvania. He is the national bestselling author of ‘Chasing My Cure: A Doctor’s Race to Turn Hope Into Action‘. He is also a patient battling a deadly disease called idiopathic multicentric Castleman disease (iMCD), which he discovered a treatment for that is saving his life and others. He has identified and advanced 15 other treatment approaches for iMCD, COVID, and cancer. Dr. David Fajgenbaum’s unique blend of physician-scientist expertise, firsthand patient experience, and success in drug repurposing will enrich Every Cure with groundbreaking insights and an unyielding passion to transform patient outcomes.
- Tracey Sikora – Ms. Sikora is Co-Founder of Every Cure. She has previously conducted pre-clinical and clinical research in rare diseases, including MPS I, Niemann-Pick Type C, Familial Hypercholesterolemia, and Castleman disease. Her research portfolio includes both novel treatments, including AAV gene therapies, and repurposed treatments. Prior to joining Every Cure, Ms. Sikora managed the CORONA Project at the University of Pennsylvania, investigating systematic evaluation of clinical trial data for Covid-19 treatments. In her current role, she leads mission-driven organizational operations.
This newly expanded executive team represents a strategic enhancement to Every Cure’s leadership structure, reflecting our commitment to advancing our mission with increased vigor and expertise. Their diverse backgrounds in drug development, artificial intelligence, operational strategy, and development work synergistically to bolster our organizational capacity. This allows us to accelerate our research and development efforts, optimize our operational frameworks, and expand our outreach and impact within the healthcare community. Through their guidance, Every Cure aims to transform the treatment landscape globally, ultimately improving health outcomes and enhancing the quality of life for countless individuals.
For more information on Every Cure’s initiatives and to learn how you can contribute, visit EveryCure.org.
For further information or to express interest in partnering with Every Cure, please contact us at [email protected]
***
About Every Cure
Every Cure is a nonprofit organization dedicated to unlocking the full potential of every existing medicine to treat every disease possible. Repurposing existing drugs is the fastest and most efficient way to treat diseases with the greatest return on investment for saving lives. However, systemic barriers impede repurposing, so patients suffer while potential treatments are not fully utilized. Every Cure overcomes these barriers to systematically identify and advance promising repurposing opportunities and save lives. Every Cure is taking a revolutionary and disruptive approach to overcome these systemic barriers by developing a comprehensive, open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 12,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies. Every Cure announced its launch in September 2022 at the Clinton Global Initiative.
For more information, please visit EveryCure.org or connect with us on Twitter, LinkedIn, Facebook, and Instagram.